| 摘要 |
[Objectives] To investigate the clinical efficacy of duloxetine combined with ozone pain point injection for the treatment of fibromyalgia (FM) and assess the effects of this combination therapy on pain, depression, and sleep disorders. [Methods] A randomized controlled crossover design was employed in this study. Sixty inpatients diagnosed with FM were allocated into three groups: the duloxetine group, the ozone group, and the combination therapy group, with each group consisting of 20 participants. The treatment duration was set at 4 weeks. The Visual Analogue Scale (VAS), the Fibromyalgia Impact Questionnaire (FIQ), the Hamilton Depression Scale (HAMD), the Pittsburgh Sleep Quality Index (PSQI), and the number of tender points were assessed prior to treatment, 2 weeks post treatment, and 4 weeks post treatment. [Results] There were no statistically significant differences in various indicators among the three groups of patients prior to treatment. Following treatment, the VAS, FIQ, HAMD, PSQI, and the number of tender points in all three groups exhibited significant improvements (P<0.05). Notably, the combination therapy group demonstrated the most substantial reductions in each score, surpassing the improvements observed in the single application group (P<0.05). [Conclusions] Duloxetine combined with ozone pain point injection demonstrates a synergistic effect in alleviating pain, reducing depression, and enhancing sleep quality in patients with FM. This combination therapy exhibits superior efficacy compared to monotherapy and holds significant potential for clinical application. |
